The Committee on Energy and Commerce is the oldest standing legislative committee (established 1795) in the U.S. House of Representatives and is vested with the broadest jurisdiction of any congressional authorizing committee. Today, the committee has responsibility for matters including telecommunications, consumer protection, food and drug safety, public health and research, environmental quality, energy policy, and interstate and foreign commerce among others. The committee is led by Chairman Brett Guthrie (KY-02) and Ranking Member Frank Pallone (NJ-06). The Subcommittee on Health is led by Chairman Morgan Griffith (VA-09) and Ranking Member Diana DeGette (CO-01).
Today's markup will further our efforts to lower health care costs for all Americans and safeguard
our communities. It builds off our most recent hearing that examined several policy proposals
to increase price transparency across the health sector and builds on President Trump's initiatives
to bring more transparency to our health system. The markup also builds on the work this subcommittee
did in passing the Halt Fentanyl Act led by myself and Mr. Latta and the Support Act
for Patients and Communities Reauthorization Act led by Chairman Guthrie, both of which President
Trump signed into law last year. Health care costs remain one of the most important challenges
facing American patients, families and employers. Today's health system can be complex and difficult
to navigate, leaving many Americans without clear information about the cost or quality of care
they receive. Patients are often asked to make important decisions without clear information
about what the costs are that they might face. Whether a provider is in network,
out of network, or what alternative treatment options might be available. Even those who
carefully plan medical expenses can be surprised by bills that arrive weeks or months after
receiving care. The current lack of transparency leaves patients in the dark and limits their
ability to make informed care decisions. At a time when consolidation among insurers and providers
continues to reduce competition and drive up prices, transparency serves as a potential solution
to empower consumer choice, improve health care outcomes, and ultimately lower costs.
That is why we need to continue to move these critical bills across the finish line. Understand,
we know there is more work that needs to be done to refine many of these bills between
subcommittee action today and the full committee markup. But this is something that has been
important to both sides of the aisle, and I look forward to continuing our work. One of the bills
under consideration is the Lower Cost, More Transparency Act, which is a continuation of our
transparency work from last Congress. The bill codifies many of the regulations implemented by
the Trump administration and aims to bolster transparency and compliance. It does so by
requiring hospitals and providers to publicly post prices for their services, and it standardizes
information for these charges and services provided by these entities. Some of the other transparency
bills in front of us today will bring more accountability and visibility into commercial
and Medicare Advantage insurance plans. Several relate to prior authorization so individuals can
see the percentage of health claims approved or denied in a plan year. Another bill aims to bring
transparency into premium dollars, which can help consumers better understand how plans are using
their premium dollars. The Medical Loss Ratio, or MLR, was created under the so-called Affordable
Care Act, and it is the percentage of premium dollars spent by an insurance company on medical
care outside of administrative costs or profits. As we heard in our Health Care Affordability
Series hearings, there is a gaming of this accountability measure. Incorporating increased
transparency into plans and premiums helps provide clarity as to where premium dollars are being
spent by insurance companies and how much of it is actually going toward beneficiary care.
Additionally, there are several bills under consideration that continue our efforts
into the illicit drug space. One of the bills is the Combating Illicit Xylosine Act, which would
classify xylosine as a Schedule III under Controlled Substances Act, while also protecting its legitimate
use in large animal veterinary medicine. The bill is important to my district because,
according to the National Cattlemen's Association, Virginia's 9th district is the largest cattle
congressional district east of the Mississippi, and my district is physically home to two
veterinary schools. Another important bill before us is Tyler's Law, which requires the
Department of Health and Human Services, or HHS, to study and issue guidance on whether hospitals
should implement fentanyl testing in routine emergency department drug screens. Lastly,
we will consider a couple of bills involving community health centers, one of which is led
by Vice Chairwoman Harshberger. That bill would allow for some community health center funding to
be used for nutrition education and chronic disease prevention initiatives. I look forward
to continuing our work on these policies and advancing them to the full committee.